Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: Opportunity knocks in Myanmar health market

After a visit to Myanmar, Jiadi Yu, principal investment officer at the IFC in Hong Kong, is optimistic about the country’s health market.

Myanmar is an exciting place for investors. The new government led by Aung San Suu Kyi is encouraging private sector development and foreign investment. The country is gradually opening itself up for business to the rest of the world.

IFC is glad to be part of the process. Since setting up an office in Yangon in 2012, we have focused our investments on building up road and power infrastructure. We are keeping a watchful eye on the health sector – hence my recent visit, where I met several local top tier private healthcare providers.  

Development of the healthcare system is strongly tied to improvements in general infrastructure. The electricity sector is a particular bottleneck. Just 30% of Myanmar’s 54 million residents have access to power. Hospitals cope with the power supply shortage by installing their own generators. But lack of infrastructure explains partly why there are no medical device manufacturers and few pharma producers in the country. Myanmar’s medical drug market was worth US$390 million in 2014. Much of this was in the form of generics imported from India.

The health system is very public sector-led, with public facilities comprising 86% of the total. The private sector is expanding, however. There are now 205 private hospitals, most of them small in size – the largest one I visited in Yangon has 220 beds, and roughly 90% have fewer than 100 beds.  

On the demand side, non-communicable diseases are a growing problem, accounting for 60% of deaths in 2015. Infectious diseases remain a threat too. The country has, for example, one of the highest tuberculosis rates in Asia.  

The supply of health services, however, falls far short of demand. Myanmar’s rich, for instance, often travel abroad for procedures – from check-ups to heart surgery to cancer treatment. They spend US$250 million on medical tourism, with Thailand, Singapore, and India the top destinations. Some of this money could be kept inside the country if higher quality healthcare options were available. The good news is that local sponsors are planning a number of greenfield hospitals targeting this segment of the market.

A significant barrier to accessing healthcare services is the low penetration rate for health insurance. Myanmar has one of the highest out-of-pocket expenditure rates in the region – close to 70% in 2015.

What I found perhaps most striking about Myanmar’s healthcare system is the severe shortage of human capital, especially nurses. Each year, the country churns out 1,300 medical graduates – but only 400 nursing graduates. Myanmar is the only country in southeast Asia where there are more doctors than nurses graduating. Public hospitals take up almost all of the nursing graduates, leaving private hospitals struggling to find the nurses they need.

The private hospitals I visited meet this challenge in different ways. Some train healthcare assistants to supplement the nurses; some send new recruits to the Philippines for training; and some hire foreign nurses to train the local nurses. All told me that they would like to set up their own nursing school and expect the government to grant their operating license soon. These private nursing programmes will help to alleviate the manpower shortage.

There is a shortage of doctors too – at least in the private facilities. There is no private medical college in Myanmar. All doctors, once they acquire their specialisation, are contractually bound to serve in public hospitals for at least five years. Private hospitals are grappling to access specialists in public hospitals by offering consultants positions but that means they may arrive at their clinic after doing a full days’ work at a public facility. In addition, many doctor graduates, discouraged by the low salaries offered at home, have moved to neighbouring countries such as Singapore or Thailand over the past decades. The tide may be turning, however: in the past couple of years, some overseas specialists have been enticed back by increasing opportunities in the private sector. 

Overall, I left Myanmar feeling upbeat.  With the government easing restrictions on foreign and private investment, and patient demand for better quality healthcare services on the rise, Myanmar’s health market is pregnant with possibilities. The government has adopted a goal of achieving universal health care by 2030 so we can expect expenditures to grow significantly. Private investors will be a big part of the market’s development and IFC plans to be at the table.

Posted on: 21/04/2017 UTC+08:00


News

China Cord Blood Corporation (CCBC), the country’s largest provider of cord blood storage and ancillary services, has reported a 38.7% rise in profits for the full year to 31 March of Rmb126.2 million (US$18.3 million). At the same time, revenues were up 14.6% to Rmb760 million.
Beijing-based Baheal Pharmaceutical Group plans to bring IBM Watson Health’s Watson for Genomics to clinicians across China. The new multi-year agreement comes less than three months after Baheal and IBM launched a strategic alliance to distribute Watson for Oncology in China. The plan is to establish an ecosystem within China to sell the molecular data interpretation technology to clinicians and researchers across the country. Financial terms have not been disclosed.
Medical insurance provider ALC Health has been confirmed as a Lloyd's Coverholder in Hong Kong. ALC Health, a subsidiary of global benefits and assistance services provider International Medical Group, has also opened an office in Hong Kong, appointing Harry Amende as business development executive.
Malaysian examination glove manufacturer Comfort Glove has reported a profit of M$10.1 million (US$2.4 million) for the first quarter of the year. This is a significant increase on the same period last year when the company was hit by a fire. Quarter-on-quarter, revenues were up 29% to M$93.7 million.
Thanks to listing costs, Hong Kong care home operator Pine Care Group has reported a 54.5% slump in profits for the year to 31 March to HK$12.4 million (US$1.6 million). At the same time, revenues were up 2.6% to HK$177.3 million.
Shares in Sydney-based medical appointment booking service 1st Group jumped 22.2% yesterday after the group announced an agreement with Australian leading health advertising and content provider, Tonic Health Media.
Shares in Australian medtech company Resonance Health rose 3.7% yesterday after Thalassaemia International Federation (TIF), a leading patient organisation in the field of iron overload, endorsed its technology which measures liver iron concentration.
US life science technology company Sanovas has agreed to set up a US$75 million venture capital fund and innovation centre with the People's Government of Suzhou. The centre will be based at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences located within the Suzhou Industrial Park Biotechnology Innovation Centre.



Analysis

Brisbane-based Oventus has had a good week. First and foremost the sleep disorder device manufacturer has just completed the first tranche of capital raising. It has raised A$6.5 million (US$4.9 million) in a placement of shares at A$0.36 per share. A second tranche to raise A$0.5 million will follow subject to shareholder approval. Bell Potter is managing the deal.
A new report from QBE Insurance, Australia's largest global insurer, reveals that 22% of healthcare companies in Hong Kong have suffered from legal and regulatory compliance issues over the past 12 months. The Risks of Regret report looks at both current and future business challenges and opportunities, and how well-prepared companies are to deal with risks.
“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.
Susann Roth, senior social development specialist, Asian Development Bank, explains why the ADB is committed to doubling health sector investments by 2020.
SGX-listed private healthcare provider Health Management International (HMI) has reported an actual loss in profits for the third quarter of the year of M$1.6 million (US$370,000), though stripping out exceptional items, profits were up 12% to M$7.1 million. The loss was predominantly down to one-off fees of M$7.3 million incurred during the group’s M$556.5 million consolidation of its two hospitals in Malaysia, however profits were also eroded by M$1.3 million in forex losses thanks to a weakening ringgit.
Shares in Cayman Islands-incorporated G Medical Innovations, which develops mobile health technologies, declined heavily on their ASX debut yesterday, dropping 30%.
Singapore-listed property developer Perennial Real Estate has reported a 356% rise in profits for the first quarter of the year to S$38.7 million (US$27.5 million) thanks to divestment gains in Singapore. Revenues for the same period slumped 31.5% to S$20.2 million largely due to lower project management fees and lower rental revenue.
First quarter results from Indonesian healthcare companies have been subdued. There is a sense of marking time rather than any major move forward for any of them. Indeed with the exception of Siloam International Hospitals, the country’s largest private hospital operator, the share price of its healthcare rivals are all showing a loss for the year.



The Future of Healthcare in Asia

Round table

Download the round table here




Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices